STOCK TITAN
  1. Home
  2. Sec-filings
  3. RLAY
  4. [Form 4] Relay Therapeutics, Inc. Insider Trading Activity

Relay Therapeutics (RLAY) director granted option on 32,947 shares at $14.09

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Relay Therapeutics, Inc. director Lonnel Coats received a new stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted on June 9, 2026 as compensation, not an open-market purchase.

The option vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, and expires on June 8, 2036. Following this grant, Coats holds stock options for 32,947 underlying shares directly.

Positive

  • None.

Negative

  • None.
Insider COATS LONNEL
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 32,947 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 32,947 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Option grant size 32,947 shares Stock option covering common stock granted June 9, 2026
Exercise price $14.09/share Exercise price for the 32,947-share stock option
Expiration date June 8, 2036 Option term end date for granted stock option
Post-grant option holdings 32,947 shares Total underlying shares following this option grant
Transaction code A Grant, award, or other acquisition of derivative securities
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
grant/award acquisition financial
"transaction_action: "grant/award acquisition""
annual meeting of stockholders financial
"vests in full on the earlier to occur of ... the date of the next annual meeting of stockholders"
expiration date financial
"expiration_date: "2036-06-08T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
COATS LONNEL
(Last)(First)(Middle)
C/O RELAY THERAPEUTICS, INC.
60 HAMPSHIRE STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02139
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$14.0906/09/2026A32,947 (1)06/08/2036Common Stock32,947$032,947D
Explanation of Responses:
1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.
/s/ Soo-Yeun Lim, as Attorney-in-Fact06/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Relay Therapeutics (RLAY) director Lonnel Coats report on this Form 4?

Lonnel Coats reported receiving a stock option grant for 32,947 shares of Relay Therapeutics common stock. The grant is a compensation award, not an open-market trade, and is documented as an acquisition of derivative securities on June 9, 2026.

What are the key terms of Lonnel Coats’ new Relay Therapeutics (RLAY) stock option?

The stock option covers 32,947 shares of Relay Therapeutics common stock at an exercise price of $14.09 per share. It was granted on June 9, 2026 and expires on June 8, 2036, giving Coats a long-dated right to buy shares at that price.

How and when does Lonnel Coats’ Relay Therapeutics (RLAY) option grant vest?

The option vests in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders. This single-vesting schedule means the full 32,947-share option becomes exercisable at that time.

Is Lonnel Coats buying or selling Relay Therapeutics (RLAY) shares in this filing?

No open-market buying or selling occurred. The Form 4 shows a grant of a stock option, classified as a grant or award acquisition. Coats received rights to purchase 32,947 shares at $14.09, but no common shares were bought or sold in the market.

What is Lonnel Coats’ Relay Therapeutics (RLAY) option position after this transaction?

After the grant, Coats directly holds a stock option over 32,947 underlying shares of Relay Therapeutics common stock. The filing does not list additional derivative positions, so this option represents the position shown in this specific Form 4 disclosure.